[go: up one dir, main page]

ZA201308069B - FORMULATION FOR ANTI-a4b7 ANTIBODY - Google Patents

FORMULATION FOR ANTI-a4b7 ANTIBODY

Info

Publication number
ZA201308069B
ZA201308069B ZA2013/08069A ZA201308069A ZA201308069B ZA 201308069 B ZA201308069 B ZA 201308069B ZA 2013/08069 A ZA2013/08069 A ZA 2013/08069A ZA 201308069 A ZA201308069 A ZA 201308069A ZA 201308069 B ZA201308069 B ZA 201308069B
Authority
ZA
South Africa
Prior art keywords
antibody
formulation
Prior art date
Application number
ZA2013/08069A
Other languages
English (en)
Inventor
Catherine Scholz
Irving H Fox
Jason Brown
Vaithanathan Palaniappan
Csanad M Varga
Nobel T Truong
Willow Diluzio
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085207&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201308069(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of ZA201308069B publication Critical patent/ZA201308069B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2013/08069A 2011-05-02 2013-10-29 FORMULATION FOR ANTI-a4b7 ANTIBODY ZA201308069B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161481533P 2011-05-02 2011-05-02
US201161550545P 2011-10-24 2011-10-24
US201261585859P 2012-01-12 2012-01-12
PCT/US2012/036072 WO2012151248A2 (en) 2011-05-02 2012-05-02 FORMULATION FOR ANTI-α4β7 ANTIBODY

Publications (1)

Publication Number Publication Date
ZA201308069B true ZA201308069B (en) 2016-01-27

Family

ID=46085207

Family Applications (3)

Application Number Title Priority Date Filing Date
ZA2013/08069A ZA201308069B (en) 2011-05-02 2013-10-29 FORMULATION FOR ANTI-a4b7 ANTIBODY
ZA2017/07158A ZA201707158B (en) 2011-05-02 2017-10-20 FORMULATION FOR ANTI-A4ß7 ANTIBODY
ZA2018/06946A ZA201806946B (en) 2011-05-02 2018-10-18 FORMULATION FOR ANTI-A4ß7 ANTIBODY

Family Applications After (2)

Application Number Title Priority Date Filing Date
ZA2017/07158A ZA201707158B (en) 2011-05-02 2017-10-20 FORMULATION FOR ANTI-A4ß7 ANTIBODY
ZA2018/06946A ZA201806946B (en) 2011-05-02 2018-10-18 FORMULATION FOR ANTI-A4ß7 ANTIBODY

Country Status (41)

Country Link
US (14) US20120282249A1 (zh)
EP (4) EP3329965B1 (zh)
JP (7) JP6190360B2 (zh)
KR (7) KR101923371B1 (zh)
CN (4) CN108129565B (zh)
AR (1) AR086237A1 (zh)
AU (6) AU2012250873B2 (zh)
BR (1) BR112013028424A2 (zh)
CA (2) CA2834867C (zh)
CL (2) CL2013003146A1 (zh)
CO (1) CO6801647A2 (zh)
CR (1) CR20130677A (zh)
CY (1) CY1119435T1 (zh)
DK (1) DK2704798T3 (zh)
DO (1) DOP2013000253A (zh)
EA (1) EA032729B1 (zh)
EC (2) ECSP13013050A (zh)
ES (1) ES2645187T3 (zh)
GE (1) GEP201706734B (zh)
HK (2) HK1249466A1 (zh)
HR (1) HRP20171432T1 (zh)
HU (1) HUE036663T2 (zh)
IL (5) IL296838A (zh)
LT (1) LT2704798T (zh)
MA (1) MA35136B1 (zh)
ME (1) ME02859B (zh)
MX (3) MX348814B (zh)
MY (2) MY183471A (zh)
PE (2) PE20141175A1 (zh)
PH (3) PH12013502236A1 (zh)
PL (1) PL2704798T3 (zh)
PT (1) PT2704798T (zh)
RS (1) RS56397B1 (zh)
SG (1) SG194652A1 (zh)
SI (1) SI2704798T1 (zh)
SM (1) SMT201700508T1 (zh)
TW (3) TWI556828B (zh)
UA (2) UA116189C2 (zh)
UY (1) UY34053A (zh)
WO (1) WO2012151248A2 (zh)
ZA (3) ZA201308069B (zh)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CN104531671A (zh) 2010-10-01 2015-04-22 现代治疗公司 设计核酸及其使用方法
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
PH12018502221B1 (en) * 2011-05-02 2023-05-10 Millennium Pharm Inc FORMULATION FOR ANTI-a4ß7 ANTIBODY
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
BR112014007852B1 (pt) 2011-10-03 2021-11-03 Moderna Therapeutics, Inc Polinucleotídeo isolado modificado e composição farmacêutica
AU2012352180A1 (en) 2011-12-16 2014-07-31 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
WO2013151672A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of oncology-related proteins and peptides
RS63237B1 (sr) 2012-11-26 2022-06-30 Modernatx Inc Terminalno modifikovana rnk
TR201905313T4 (tr) * 2013-03-15 2019-05-21 Abbvie Deutschland Anti-EGFR antikoru ilaç konjugat formülasyonları.
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
JP2016538829A (ja) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 低密度リポタンパク質受容体をコードするポリヌクレオチド
ES2910443T3 (es) * 2014-04-16 2022-05-12 Biocon Ltd Formulaciones de proteínas estables que comprenden un exceso molar de sorbitol
CA2960876C (en) 2014-10-06 2024-02-13 Chemocentryx, Inc. Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) * 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
MA41636A (fr) * 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
SG10201913748QA (en) * 2015-08-11 2020-03-30 Univ Osaka Antibody
WO2017087735A1 (en) * 2015-11-18 2017-05-26 Millennium Pharmaceuticals, Inc. Method for treating crohn's disease
USD866757S1 (en) 2016-03-11 2019-11-12 Millennium Pharmaceuticals, Inc. Autoinjector
JP2019508448A (ja) * 2016-03-14 2019-03-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 移植片対宿主病予防の方法
KR102667332B1 (ko) * 2016-03-14 2024-05-20 밀레니엄 파머슈티컬스 인코퍼레이티드 이식편대숙주 질환을 치료하거나 예방하는 방법
WO2017158393A1 (en) * 2016-03-18 2017-09-21 Oslo University Hospital Hf Methods of treating graft-versus-host disease
MA44483A (fr) 2016-03-24 2019-01-30 Millennium Pharm Inc Procédés pour traiter des événements indésirables gastro-intestinaux d'origine immunitaire dans des traitements oncologiques immunitaires
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
ES2962373T3 (es) * 2016-04-13 2024-03-18 Medimmune Llc Uso de aminoácidos como compuestos estabilizadores en composiciones farmacéuticas que contienen altas concentraciones de agentes terapéuticos basados en proteínas
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
US11389533B2 (en) 2016-06-12 2022-07-19 Takeda Pharmaceutical Company Limited Method of treating inflammatory bowel disease
KR20230164205A (ko) * 2016-10-07 2023-12-01 리제너론 파아마슈티컬스, 인크. 실온 안정성 동결건조된 단백질
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
EP3558391B1 (en) * 2016-12-23 2022-02-02 Immunogen, Inc. Immunoconjugates targeting adam9 and methods of use thereof
CA3061320A1 (en) 2017-04-28 2018-11-01 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders
US10646569B2 (en) 2017-05-16 2020-05-12 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
KR20200011457A (ko) * 2017-05-26 2020-02-03 밀레니엄 파머슈티컬스 인코퍼레이티드 만성 맹낭염의 치료 방법
MY198425A (en) 2017-08-24 2023-08-29 Novo Nordisk As Glp-1 Compositions and uses Thereof
TWI648098B (zh) 2017-11-14 2019-01-21 亞智科技股份有限公司 氣液混合機構、製程設備及氣液混合方法
US20210031012A1 (en) 2018-01-26 2021-02-04 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor
AU2019253070A1 (en) * 2018-04-10 2020-11-26 Dr. Reddy's Laboratories Limited Antibody formulation
BR112020020741A2 (pt) * 2018-04-10 2021-01-19 Dr. Reddy's Laboratories Limited Formulação farmacêutica estável de um anticorpo, e, formulação de anticorpo alfa4beta7 estável.
JP2021521171A (ja) * 2018-04-10 2021-08-26 ドクター レディズ ラボラトリーズ リミテッド 治療用抗体の安定な製剤
US12240903B2 (en) 2018-05-31 2025-03-04 Ono Pharmaceutical Co., Ltd. Biomarkers for determining the effectiveness of immune checkpoint inhibitors
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3810268A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
US20230312700A1 (en) 2018-06-20 2023-10-05 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
CN109239335A (zh) * 2018-09-11 2019-01-18 广州万孚生物技术股份有限公司 联检试纸条及其制备方法
WO2020123241A1 (en) * 2018-12-10 2020-06-18 Clear Creek Bio, Inc. Multiphasic dosing regimens for treating cancer
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
WO2020252069A1 (en) * 2019-06-10 2020-12-17 Millennium Pharmaceuticals, Inc. METHODS OF PRODUCING AN ANTI-α4β7 ANTIBODY
JP2022536658A (ja) * 2019-06-10 2022-08-18 武田薬品工業株式会社 抗体生産のための細胞培養方法及び組成物
US10792360B1 (en) 2019-11-21 2020-10-06 Chemocentryx, Inc. Compositions and methods for treating inflammatory bowel disease using CCR9 inhibitor and anti-TNF-alpha blocking antibodies
US20230082544A1 (en) 2020-02-18 2023-03-16 Novo Nordisk A/S Pharmaceutical formulations
CN113577281A (zh) * 2020-04-30 2021-11-02 中国科学院分子细胞科学卓越创新中心 调控整合素β亚基的试剂和方法
UY39327A (es) 2020-07-16 2022-02-25 Abbvie Inc Anticuerpos anti- alpha-4-beta-7
US20240100158A1 (en) * 2021-01-20 2024-03-28 Dr. Reddy’S Laboratories Limited Freeze dried antibody formulations and methods thereof
US20240239900A1 (en) * 2021-05-07 2024-07-18 Dr. Reddy’S Laboratories Limited A method of improving stability of an antibody formulation
CN113813377A (zh) * 2021-09-07 2021-12-21 杭州远大生物制药有限公司 抗α4β7抗体制剂及其应用
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US774216A (en) 1903-11-19 1904-11-08 Alexander F Ward Machine for pointing and lapping hoops.
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5538724A (en) 1987-08-11 1996-07-23 The Board Of Trustees For The Leland Stanford Junior Univ. Method of control leukocyte extravasation
ATE114478T1 (de) 1987-08-11 1994-12-15 Univ Leland Stanford Junior Verfahren zur kontrolle der leukozyten- extravasation.
US5403919A (en) 1987-08-11 1995-04-04 Board Of Trustees Of The Leland Stanford Junior University Stanford University Method to control leukocyte extravasation
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US5223392A (en) 1988-01-25 1993-06-29 Exocell, Inc. Monoclonal antibodies against glycated albumin, hybrid cell lines producing these antibodies, and use therefore
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
EP0462111A4 (en) 1988-12-23 1992-07-08 The Board Of Trustees Of The Leland Stanford Junior University Homing sequences and their uses
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5730978A (en) 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
IL113261A (en) 1989-09-01 1996-10-16 Hutchinson Fred Cancer Res Inhibition by peptides of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction and pharmaceutical compositions containing said peptides
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5665595A (en) 1991-06-07 1997-09-09 Dowelanco Immunoglobulins against insect tissue
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
US5871734A (en) 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
ATE151642T1 (de) 1992-02-12 1997-05-15 Biogen Inc Behandlung für entzündungserkrankung des darmes
AU4390893A (en) 1992-05-21 1993-12-13 Center For Blood Research, Inc., The A novel receptor for alpha4 integrins and methods based thereon
AU5732694A (en) 1992-12-01 1994-06-22 Protein Design Labs, Inc. Humanized antibodies reactive with cd18
AU5675794A (en) 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression
AU688751B2 (en) 1993-01-12 1998-03-19 Biogen Idec Ma Inc. Recombinant anti-VLA4 antibody molecules
DK0682529T4 (da) 1993-02-09 2006-05-15 Biogen Idec Inc Antistof til behandling af insulinkrævende diabetes
US6017695A (en) 1993-03-26 2000-01-25 Becton Dickinson And Company Nucleic acids encoding human cell adhesion molecule
JPH06303990A (ja) 1993-04-24 1994-11-01 Kanebo Ltd モノクローナル抗体、それを産生するハイブリドーマおよび該抗体の製造方法
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
ES2424292T3 (es) 1994-01-25 2013-09-30 Biogen Idec Ma Inc. Anticuerpos humanizados contra la molécula de adhesión leucocitaria VLA-4
US5594120A (en) 1994-02-18 1997-01-14 Brigham And Women's Hospital, Inc. Integrin alpha subunit
US5610281A (en) 1994-05-03 1997-03-11 Brigham & Women's Hospital, Inc. Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes
GB2292079B (en) 1994-08-12 1998-07-15 Flexpharm Ltd Coated prednisolone preparation for the treatment of inflamatory bowel disease
US5624321A (en) 1994-12-23 1997-04-29 Snyder; Stephen D. Spring-actuated swing device
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
ES2290955T3 (es) 1995-02-10 2008-02-16 Millennium Pharmaceuticals, Inc. Adresinas vasculares de mucosas y sus usos.
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6037324A (en) 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
US6015662A (en) 1996-01-23 2000-01-18 Abbott Laboratories Reagents for use as calibrators and controls
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US20010046496A1 (en) * 2000-04-14 2001-11-29 Brettman Lee R. Method of administering an antibody
EP1409018B1 (en) 2001-07-25 2010-01-06 Facet Biotech Corporation Stable lyophilized pharmaceutical formulation the igg antibody daclizumab
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
DE10163459A1 (de) 2001-12-21 2003-07-03 Merck Patent Gmbh Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor
PT2336184E (pt) 2002-02-25 2015-03-09 Biogen Idec Inc Administração de agentes para o tratamento da inflamação
EP1507756B1 (en) 2002-05-24 2015-07-22 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
WO2004046092A2 (en) 2002-11-18 2004-06-03 Chemocentryx Aryl sulfonamides
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
DK2335725T3 (en) 2003-04-04 2017-01-23 Genentech Inc Highly concentrated antibody and protein formulations
MY162179A (en) * 2004-04-01 2017-05-31 Elan Pharm Inc Steroid sparing agents and methods of using same
CN104710532B (zh) 2004-09-03 2019-01-18 健泰科生物技术公司 人源化的抗-β7拮抗剂及其应用
WO2007061679A1 (en) 2005-11-17 2007-05-31 Millennium Pharmaceuticals, Inc. HUMANIZED IMMUNOGLOBULIN REACTIVE WITH α4β7 INTEGRIN
JP5231810B2 (ja) 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
US20080071063A1 (en) 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
AR060487A1 (es) 2006-04-21 2008-06-18 Xoma Technology Ltd Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
AU2007307107B2 (en) 2006-10-06 2011-11-03 Amgen Inc. Stable antibody formulations
JP5623743B2 (ja) 2006-10-20 2014-11-12 アムジエン・インコーポレーテツド 安定なポリペプチド製剤
EP2109480B1 (en) 2006-12-07 2017-06-28 The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services Use of antagonists of the interaction between hiv gp120 and alpha4beta7 integrin
MX2009006199A (es) 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
WO2009020654A1 (en) * 2007-08-08 2009-02-12 Abbott Laboratories Compositions and methods for crystallizing antibodies
WO2010100200A2 (en) * 2009-03-05 2010-09-10 Novartis Ag Lyophilised antibody formulation
TWI466681B (zh) 2009-03-20 2015-01-01 Amgen Inc α４β７雜二聚體專一性拮抗抗體
JP2012530721A (ja) * 2009-06-18 2012-12-06 ワイス・エルエルシー 小モジュール免疫薬のための凍結乾燥製剤
WO2011017070A1 (en) 2009-07-28 2011-02-10 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
AU2012236304C1 (en) 2011-03-31 2017-01-05 Genentech, Inc. Methods of administering beta7 integrin antagonists
PH12018502221B1 (en) 2011-05-02 2023-05-10 Millennium Pharm Inc FORMULATION FOR ANTI-a4ß7 ANTIBODY
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) * 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
JP6904905B2 (ja) 2014-12-24 2021-07-21 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗α４β７インテグリン抗体による治療の結果の予測
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease

Also Published As

Publication number Publication date
KR20180050435A (ko) 2018-05-14
US20180289811A1 (en) 2018-10-11
JP2019108400A (ja) 2019-07-04
BR112013028424A2 (pt) 2021-05-04
JP2023076616A (ja) 2023-06-01
AU2012250873B2 (en) 2016-07-07
CN103608071B (zh) 2017-12-26
EP3329965B1 (en) 2025-03-19
IL267668B (en) 2020-10-29
US20190076532A1 (en) 2019-03-14
CA3028209A1 (en) 2012-11-08
AU2012250873A1 (en) 2013-05-09
US9663579B2 (en) 2017-05-30
AU2020250249B2 (en) 2022-10-06
JP6878489B2 (ja) 2021-05-26
UA126545C2 (uk) 2022-11-02
KR20140145953A (ko) 2014-12-24
AU2018278866A1 (en) 2019-01-03
EP4378484A2 (en) 2024-06-05
JP7258941B2 (ja) 2023-04-17
UY34053A (es) 2012-11-30
AU2016231469B2 (en) 2018-12-20
IL267668A (en) 2019-08-29
KR20180127540A (ko) 2018-11-28
DOP2013000253A (es) 2013-12-31
TW201906631A (zh) 2019-02-16
PH12013502236A1 (en) 2014-01-06
CN108079291A (zh) 2018-05-29
IL296847A (en) 2022-11-01
US20140377251A1 (en) 2014-12-25
IL296838A (en) 2022-11-01
ECSP13013050A (es) 2014-01-31
AU2018278866B2 (en) 2020-07-09
PH12020500336A1 (en) 2021-02-22
UA116189C2 (uk) 2018-02-26
MA35136B1 (fr) 2014-05-02
MX2021006723A (es) 2022-05-03
ES2645187T3 (es) 2017-12-04
CR20130677A (es) 2014-10-07
AR086237A1 (es) 2013-11-27
AU2022231726A1 (en) 2022-10-06
EP4378484A3 (en) 2024-09-04
US20120282249A1 (en) 2012-11-08
CO6801647A2 (es) 2013-11-29
TW201247223A (en) 2012-12-01
US20220370617A1 (en) 2022-11-24
KR102096484B1 (ko) 2020-04-02
IL229104A0 (en) 2013-12-31
US20170002078A1 (en) 2017-01-05
CA2834867A1 (en) 2012-11-08
CY1119435T1 (el) 2018-03-07
HRP20171432T1 (hr) 2017-11-03
KR101923371B1 (ko) 2018-11-29
CA3028209C (en) 2021-01-05
GEP201706734B (en) 2017-09-25
SMT201700508T1 (it) 2017-11-15
CL2017000830A1 (es) 2017-12-22
US20200206353A1 (en) 2020-07-02
SI2704798T1 (sl) 2017-12-29
CN108129565B (zh) 2022-09-20
PH12018500030B1 (en) 2022-05-04
EP3329965A1 (en) 2018-06-06
US20250041424A1 (en) 2025-02-06
MY172735A (en) 2019-12-11
JP7492057B2 (ja) 2024-05-28
AU2022231726B2 (en) 2025-01-09
US20180207279A1 (en) 2018-07-26
AU2019201926A1 (en) 2019-04-11
CN108187042A (zh) 2018-06-22
KR20170116217A (ko) 2017-10-18
JP6534415B2 (ja) 2019-06-26
MX2013012724A (es) 2013-12-06
US9764033B2 (en) 2017-09-19
TW201718012A (zh) 2017-06-01
CA2834867C (en) 2019-02-12
US12171832B2 (en) 2024-12-24
IL275038B (en) 2022-11-01
ZA201707158B (en) 2019-01-30
US10004808B2 (en) 2018-06-26
MX356827B (es) 2018-06-15
ECSP22034515A (es) 2022-05-31
EA201391614A1 (ru) 2014-07-30
US20190231878A1 (en) 2019-08-01
EP2704798B1 (en) 2017-07-12
KR101923378B1 (ko) 2018-11-29
KR20220154834A (ko) 2022-11-22
LT2704798T (lt) 2017-10-25
JP6473845B2 (ja) 2019-02-20
EP3329965A3 (en) 2018-12-12
TWI664980B (zh) 2019-07-11
JP2024098027A (ja) 2024-07-19
CN108079291B (zh) 2022-04-08
IL275038A (en) 2020-07-30
PH12018500030A1 (en) 2018-10-15
PE20141175A1 (es) 2014-09-25
RS56397B1 (sr) 2017-12-29
JP2021113223A (ja) 2021-08-05
JP2014514346A (ja) 2014-06-19
US20160340432A1 (en) 2016-11-24
US20210052733A1 (en) 2021-02-25
EP2704798A2 (en) 2014-03-12
EP3263178A1 (en) 2018-01-03
US10143752B2 (en) 2018-12-04
EA032729B1 (ru) 2019-07-31
HK1256106A1 (zh) 2019-09-13
US20160340431A1 (en) 2016-11-24
DK2704798T3 (en) 2017-10-23
WO2012151248A3 (en) 2013-02-28
PL2704798T3 (pl) 2017-12-29
MY183471A (en) 2021-02-19
JP2017137351A (ja) 2017-08-10
SG194652A1 (en) 2013-12-30
MX348814B (es) 2017-06-30
JP2018150388A (ja) 2018-09-27
TWI556828B (zh) 2016-11-11
NZ617833A (en) 2016-04-29
CN108129565A (zh) 2018-06-08
TWI664978B (zh) 2019-07-11
HUE036663T2 (hu) 2018-07-30
AU2020250249A1 (en) 2020-11-05
PT2704798T (pt) 2017-11-14
CL2013003146A1 (es) 2014-07-25
KR20200035503A (ko) 2020-04-03
KR102275603B1 (ko) 2021-07-08
AU2016231469A1 (en) 2016-10-06
KR20210084711A (ko) 2021-07-07
WO2012151248A2 (en) 2012-11-08
CN103608071A (zh) 2014-02-26
HK1249466A1 (zh) 2018-11-02
PE20190405A1 (es) 2019-03-14
KR102465394B1 (ko) 2022-11-09
ZA201806946B (en) 2022-03-30
ME02859B (me) 2018-04-20
IL275038B2 (en) 2023-03-01
JP6190360B2 (ja) 2017-08-30
US20250000981A1 (en) 2025-01-02
US12053526B2 (en) 2024-08-06

Similar Documents

Publication Publication Date Title
IL290849A (en) Formulation for anti-antibody alpha 4 in cell 7
IL275038A (en) Formulation for anti-antibody alpha 4 in cell 7
IL276234B (en) Antibody compositions
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
HK1203146A1 (zh) 抗體製劑
TWI563004B (en) Anti-hxcr1 antibody